Actuate therapeutics announces details for 2025 asco annual meeting presentation on topline elraglusib phase 2 data in first-line treatment of metastatic pancreatic cancer

Chicago and fort worth, texas, may 22, 2025 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (“actuate” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (gsk-3Β), today announced the online publication of the abstract accepted as an oral presentation at the 2025 american society of clinical oncology (asco) annual meeting, to take place may 30-june 3, in chicago, illinois.
ACTU Ratings Summary
ACTU Quant Ranking